These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 37067160)

  • 21. Evaluation of HIV-1 capsid genetic variability and lenacapavir (GS-6207) drug resistance-associated mutations according to viral clades among drug-naive individuals.
    Nka AD; Bouba Y; Teto G; Semengue ENJ; Takou DK; Ngueko AMK; Fabeni L; Carioti L; Armenia D; Pabo W; Dambaya B; Sosso SM; Colizzi V; Perno CF; Ceccherini-Silberstein F; Santoro MM; Fokam J; Ndjolo A
    J Antimicrob Chemother; 2022 Dec; 78(1):272-275. PubMed ID: 36411257
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or have multidrug-resistant HIV-1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy: An executive summary.
    Cluck DB; Chastain DB; Murray M; Durham SH; Chahine EB; Derrick C; Dumond JB; Hester EK; Jeter SB; Johnson MD; Kilcrease C; Kufel WD; Kwong J; Ladak AF; Patel N; Pérez SE; Poe JB; Bolch C; Thomas I; Asiago-Reddy E; Short WR
    Pharmacotherapy; 2024 May; 44(5):354-359. PubMed ID: 38853605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiviral Activity of Lenacapavir Against Human Immunodeficiency Virus Type 2 (HIV-2) Isolates and Drug-Resistant HIV-2 Mutants.
    Smith RA; Raugi DN; Nixon RS; Seydi M; Margot NA; Callebaut C; Gottlieb GS;
    J Infect Dis; 2024 May; 229(5):1290-1294. PubMed ID: 38060982
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Indirect Treatment Comparisons of Lenacapavir Plus Optimized Background Regimen Versus Other Treatments for Multidrug-Resistant Human Immunodeficiency Virus.
    Chatzidaki I; Curteis T; Luedke H; Mezzio DJ; Rhee MS; McArthur E; Eddowes LA
    Value Health; 2023 Jun; 26(6):810-822. PubMed ID: 36566886
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lenacapavir (Sunlenca) for multidrug-resistant HIV.
    Med Lett Drugs Ther; 2023 May; 65(1675):68-70. PubMed ID: 37155250
    [No Abstract]   [Full Text] [Related]  

  • 26. Phenotypic resistance to lenacapavir and monotherapy efficacy in a proof-of-concept clinical study.
    Margot N; Vanderveen L; Naik V; Ram R; Parvangada PC; Martin R; Rhee M; Callebaut C
    J Antimicrob Chemother; 2022 Mar; 77(4):989-995. PubMed ID: 35028668
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy.
    Muccini C; Canetti D; Castagna A; Spagnuolo V
    Drug Des Devel Ther; 2022; 16():297-304. PubMed ID: 35115764
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rapid HIV-1 genotyping assay for the detection of capsid mutations.
    Margot N; Naik V; Nekkalapudi A; Boopathy A; Falkard B; Callebaut C
    J Med Virol; 2023 Dec; 95(12):e29292. PubMed ID: 38063404
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetic and pharmacodynamic evaluation of raltegravir and experience from clinical trials in HIV-positive patients.
    Calcagno A; D'Avolio A; Bonora S
    Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1167-76. PubMed ID: 26073580
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Long-acting lenacapavir protects macaques against intravenous challenge with simian-tropic HIV.
    Swanstrom AE; Gorelick RJ; Welker JL; Schmidt F; Lu B; Wang K; Rowe W; Breed MW; Killoran KE; Kramer JA; Donohue D; Roser JD; Bieniasz PD; Hatziioannou T; Pyle C; Thomas JA; Trubey CM; Zheng J; Blair W; Yant SR; Lifson JD; Del Prete GQ
    EBioMedicine; 2023 Sep; 95():104764. PubMed ID: 37625266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Darunavir: a review of its use in the management of HIV infection in adults.
    McKeage K; Perry CM; Keam SJ
    Drugs; 2009; 69(4):477-503. PubMed ID: 19323590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural and Mechanistic Bases of Viral Resistance to HIV-1 Capsid Inhibitor Lenacapavir.
    Bester SM; Adu-Ampratwum D; Annamalai AS; Wei G; Briganti L; Murphy BC; Haney R; Fuchs JR; Kvaratskhelia M
    mBio; 2022 Oct; 13(5):e0180422. PubMed ID: 36190128
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lenacapavir: Playing the Long Game in the New Era of Antiretrovirals.
    Neverette NC; Dumond JB; McMahon DK; Devanathan AS
    Clin Pharmacol Ther; 2024 Sep; ():. PubMed ID: 39323028
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lenacapavir: A Novel, Potent, and Selective First-in-Class Inhibitor of HIV-1 Capsid Function Exhibits Optimal Pharmacokinetic Properties for a Long-Acting Injectable Antiretroviral Agent.
    Subramanian R; Tang J; Zheng J; Lu B; Wang K; Yant SR; Stepan GJ; Mulato A; Yu H; Schroeder S; Shaik N; Singh R; Wolckenhauer S; Chester A; Tse WC; Chiu A; Rhee M; Cihlar T; Rowe W; Smith BJ
    Mol Pharm; 2023 Dec; 20(12):6213-6225. PubMed ID: 37917742
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The capsid revolution.
    Taylor IA; Fassati A
    J Mol Cell Biol; 2024 Apr; 15(11):. PubMed ID: 38037430
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Emerging drugs for the treatment of HIV/AIDS: a review of 2019/2020 phase II and III trials.
    Piscaglia M; Cossu MV; Passerini M; Petri F; Gerbi M; Fusetti C; Capetti A; Rizzardini G
    Expert Opin Emerg Drugs; 2021 Sep; 26(3):219-230. PubMed ID: 34176425
    [No Abstract]   [Full Text] [Related]  

  • 39. Tipranavir: PNU 140690, tipranivir.
    Drugs R D; 2006; 7(1):55-62. PubMed ID: 16620137
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.